IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.910
EU - Europa 4.927
AS - Asia 4.509
SA - Sud America 1.236
AF - Africa 250
Continente sconosciuto - Info sul continente non disponibili 247
OC - Oceania 4
Totale 22.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.588
SG - Singapore 1.382
VN - Vietnam 996
BR - Brasile 935
RU - Federazione Russa 844
IT - Italia 813
UA - Ucraina 785
CN - Cina 583
DE - Germania 461
IE - Irlanda 459
TR - Turchia 456
SE - Svezia 381
HK - Hong Kong 347
FR - Francia 293
DK - Danimarca 284
FI - Finlandia 208
GB - Regno Unito 203
KR - Corea 158
CA - Canada 133
AR - Argentina 110
BD - Bangladesh 105
IN - India 95
CI - Costa d'Avorio 94
MX - Messico 62
NL - Olanda 54
ID - Indonesia 51
EC - Ecuador 50
ZA - Sudafrica 48
IQ - Iraq 41
CO - Colombia 40
IL - Israele 34
JP - Giappone 29
PL - Polonia 29
PK - Pakistan 27
CR - Costa Rica 26
IR - Iran 26
PY - Paraguay 26
CL - Cile 25
MA - Marocco 23
PH - Filippine 22
ES - Italia 21
VE - Venezuela 21
AT - Austria 20
UZ - Uzbekistan 20
HN - Honduras 16
MY - Malesia 15
SA - Arabia Saudita 15
TT - Trinidad e Tobago 14
AZ - Azerbaigian 13
BE - Belgio 13
CW - ???statistics.table.value.countryCode.CW??? 13
EG - Egitto 13
TN - Tunisia 13
GT - Guatemala 12
PE - Perù 12
SC - Seychelles 12
SV - El Salvador 12
JM - Giamaica 11
KZ - Kazakistan 11
UY - Uruguay 11
KE - Kenya 10
BA - Bosnia-Erzegovina 9
JO - Giordania 9
PR - Porto Rico 9
TH - Thailandia 9
DZ - Algeria 8
GP - Guadalupe 8
LT - Lituania 8
KW - Kuwait 7
NP - Nepal 7
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
EU - Europa 6
LB - Libano 6
NI - Nicaragua 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
MD - Moldavia 5
PS - Palestinian Territory 5
AM - Armenia 4
AO - Angola 4
AU - Australia 4
BH - Bahrain 4
BO - Bolivia 4
BY - Bielorussia 4
KG - Kirghizistan 4
NG - Nigeria 4
PA - Panama 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
HR - Croazia 3
LK - Sri Lanka 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
BB - Barbados 2
BG - Bulgaria 2
CH - Svizzera 2
GE - Georgia 2
Totale 21.821
Salva come PNG Salva come JPEG
Città #
Ashburn 1.787
Singapore 846
Jacksonville 792
Fairfield 737
Dallas 594
Chandler 528
Dublin 452
Boardman 420
Council Bluffs 401
San Jose 328
Hong Kong 326
Ho Chi Minh City 321
Wilmington 316
Woodbridge 306
New York 261
Seattle 257
Houston 252
Des Moines 243
Cambridge 239
Hanoi 220
The Dalles 201
Ann Arbor 180
Princeton 176
Lawrence 172
San Mateo 171
Lauterbourg 150
Moscow 140
Los Angeles 135
Beijing 123
Turin 109
Milan 100
San Diego 99
Abidjan 94
Hefei 88
São Paulo 86
Munich 82
Da Nang 63
Chicago 56
Buffalo 53
Santa Clara 52
Haiphong 46
Centro 43
London 41
Helsinki 38
Montreal 32
Rio de Janeiro 32
Phoenix 31
Redmond 31
Brooklyn 30
Rome 30
Nuremberg 29
Shanghai 28
Miano 27
Ancona 26
Orem 25
Tokyo 23
Turku 23
Atlanta 22
Columbus 22
Frankfurt am Main 22
Biên Hòa 21
Johannesburg 21
Boston 20
Naples 20
Warsaw 20
Mexico City 19
San José 19
Tashkent 19
Chennai 18
Guayaquil 18
Norwalk 18
Ottawa 18
Washington 18
Dhaka 17
Guangzhou 17
Pune 17
Toronto 17
Baghdad 16
Belo Horizonte 16
Brasília 16
Ninh Bình 16
Nha Trang 15
Quito 15
Amsterdam 14
Bologna 14
Curitiba 14
Marche 14
Porto Alegre 14
Salt Lake City 14
Stockholm 14
Wuhan 14
Denver 13
Hải Dương 13
Kilburn 13
Willemstad 13
Ankara 12
Brussels 12
Cape Town 12
Asunción 11
Baku 11
Totale 13.190
Salva come PNG Salva come JPEG
Nome #
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 222
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 213
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 211
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 210
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 201
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 199
Candida guilliermondii fungemia in patients with hematologic malignancies. 195
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 193
Antimicrobial activity of polycationic peptides 192
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 190
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 188
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 181
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 179
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 172
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 170
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 170
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 168
Epidemiology and microbiology of surgical wound infections. 167
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 167
Candidemia in the elderly: What does it change? 163
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 160
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 159
Characterisation of candidemia in patients with recent surgery: A 7-year experience 159
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 159
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 158
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 158
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 157
Genotypic and phenotypic characteristics of Candida parapsilosis bloodstream isolates: Health Care Associated Infections in a teaching Hospital in Italy 153
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 153
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 152
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 151
Antifungal combinations in dermatophytes 151
Antifungal Combinations against Candida Species: From Bench to Bedside 150
Trichosporon beigelii fungaemia in an AIDS patient. 150
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 149
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 148
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 147
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 146
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 145
Candidemia in Internal Medicine: Facing the New Challenge 144
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 143
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 143
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 141
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 141
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 139
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 138
Antiretroviral therapy management and rationalisation of available resources 137
A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication 136
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 135
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 135
EUCAST technical note on posaconazole. 134
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 133
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 131
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 130
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 130
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 130
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 129
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 129
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 127
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 126
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 126
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 126
The Clinical Characteristics of Bloodstream Infections Due to Candida spp. in Patients Hospitalized in Intensive Care Units during the SARS-CoV-2 Pandemic: The Results of a Multicenter Study 125
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 125
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 125
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 124
Voriconazole and multidrug resistance in Candida albicans. 124
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 124
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 123
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 122
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 122
Clinical and molecular characteristics of KPC-producing Klebsiella pneumoniae bloodstream infections: Results of a multicentre study 122
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 121
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 121
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 121
EUCAST Technical Note on voriconazole. 121
Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort. 121
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches 120
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 119
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 118
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 118
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 117
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 117
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 117
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 117
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 117
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 116
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 115
Tolerance to amphotericin B in clinical isolates of Candida tropicalis. 115
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 115
In Vitro Activity of Novel Lipopeptides against Triazole-Resistant Aspergillus fumigatus 114
Caspofungin in combination with amphotericin B against Candida parapsilosis. 114
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 114
EUCAST technical note on Amphotericin B 114
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. 113
Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. 113
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 113
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 112
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 112
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746. 111
Totale 14.231
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.954
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.954
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022887 0 0 0 0 20 62 112 70 76 134 155 258
2022/20232.039 212 168 147 109 133 353 11 94 558 11 173 70
2023/20241.266 211 25 67 239 246 273 25 18 10 13 10 129
2024/20252.312 210 201 164 28 61 58 166 108 607 156 232 321
2025/20268.056 401 576 732 1.111 657 397 1.358 752 702 687 302 381
2026/20271.882 387 306 307 787 95 0 0 0 0 0 0 0
Totale 22.083